| 1.66 -0.01 (-0.6%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.08  |
1-year : | 2.18 |
| Resists | First : | 1.78 |
Second : | 1.87 |
| Pivot price | 1.69  |
|||
| Supports | First : | 1.64 |
Second : | 1.37 |
| MAs | MA(5) : | 1.68 |
MA(20) : | 1.7 |
| MA(100) : | 1.61 |
MA(250) : | 1.92 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 15.9 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 4.94 | Low : | 1.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IKNA ] has closed above bottom band by 11.9%. Bollinger Bands are 61.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.72 | 1.72 - 1.73 |
| Low: | 1.63 - 1.64 | 1.64 - 1.66 |
| Close: | 1.64 - 1.66 | 1.66 - 1.68 |
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Wed, 18 Sep 2024
Acadian Asset Management LLC Has $536,000 Stake in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Wed, 18 Sep 2024
Analyzing Ikena Oncology (NASDAQ:IKNA) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World
Sun, 01 Sep 2024
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Large Drop in Short Interest - MarketBeat
Fri, 12 Jul 2024
Best Momentum Stocks to Buy for July 12th - Yahoo Finance
Wed, 29 May 2024
Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing' - Markets Insider
Tue, 28 May 2024
UPDATE – Ikena Oncology Announces Strategic Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 1.387e+007 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 352 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.134e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 915.1 % |
| Return on Equity (ttm) | -27.5 % |
| Qtrly Rev. Growth | 1.84e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -90.9 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.27 |
| Dividend | 0 |
| Forward Dividend | 314720 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|